Keyword
in
Collection
Date
to
Houston Voice, No. 997, December 3, 1999
File 008
Citation
MLA
APA
Chicago/Turabian
Houston Voice, No. 997, December 3, 1999 - File 008. 1999-12-03. University of Houston Libraries. University of Houston Digital Library. Web. October 29, 2020. https://digital.lib.uh.edu/collection/montrose/item/7565/show/7543.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(1999-12-03). Houston Voice, No. 997, December 3, 1999 - File 008. Montrose Voice. University of Houston Libraries. Retrieved from https://digital.lib.uh.edu/collection/montrose/item/7565/show/7543

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, No. 997, December 3, 1999 - File 008, 1999-12-03, Montrose Voice, University of Houston Libraries, accessed October 29, 2020, https://digital.lib.uh.edu/collection/montrose/item/7565/show/7543.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, No. 997, December 3, 1999
Contributor
  • Hennie, Matthew A.
Publisher Window Media
Date December 3, 1999
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Collection
  • University of Houston Libraries Special Collections
  • LGBT Research Collection
  • Montrose Voice
Rights In Copyright
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 008
Transcript HOUSTON VOICE • DECEMBER 3, 1999 IT'S YOUR VISION... .MAKE AN INFORMED DECISION In the era of powerful anti-HIV therapy, HIV/AIDS and CMV retinitis patients, and their doctors, may be tempted to eliminate their anti-CMV medication. But will this be the right choice for you? CONFLICTING OPINIONS Medical opinions are divided on this question. Although the numbers of patients studied are small, the implications are important to consider. On the one hand, early results from some studies appear to support the view that some people with CMV retinitis, whose HIV is being controlled by highly active antiretroviral therapy (HAART), can safely stop taking their anti-CMV maintenance therapy' In contrast, other studies show that CMV retinitis can still occur, even in people with a good response to HAART.2 Furthermore, there is no test commercially available that can accurately determine if your immune system has regained its ability to fight CMV. EXPERTS ADVISE STAYING ON THERAPY Remember, HAART is not indicated for the treatment or prevention of CMV retinitis. The bottom line is that even when HAART is working well against HIV, it does not always protect people against the progression of CMV retinitis. HAART can also fail! If it does, people with HIV/AIDS will be vulnerable to CMV and other opportunistic infections. In response to these concerns, a panel of experts convened by the International AIDS Society (IAS) has recommended continuing anti-CMV maintenance therapy in people receiving HAART. According to the IAS panel, "Generally, patients in whom CMV disease has been diagnosed should be advised to continue their anti-CMV maintenance therapy as indicated because the effect of potent antiretroviral therapy on the course of CMV disease is still poorly understood."3 IT'S UP TO YOU... If you are thinking about stopping your anti-CMV maintenance therapy, talk to your doctor. And consider this: Are the benefits really worth the risks? After all, it's your vision. Be sure to talk to your doctor if you have any questions about your condition or therapy. References: I. Jabs DA et al. Am J Ophthalmol. December 1998;126:817-822. 2. Michelet C et al. AIDS. October 1998;12:1815-1822. 3. Whitley RJ et al. Arch Intern Med. May 1998:158:957-969. Roche Laboratories Inc.—leaders in the management of CMV disease. /Roche> Pharmaceuticals Roche Laboratories Inc. 340 Kingsland Street Nutley. New Jersey 07110-119! wvava.rocheusa.com Copyright 01999 hy Roche Laboratories Inc All rights reserved
File Name uhlib_31485329_n997_007.jpg